Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis

Rheumatology International

Volumn 27, Issue 10, 2007, Pages 935-939

  Venetsanopoulou, Aliki I ^a   Voulgari, Paraskevi V ^a   Alamanos, Yannis ^a   Papadopoulos, Christos G ^a   Markatseli, Theodora E ^a   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Ankylosing spondylitis; Efficacy; Infliximab survival; Long term; Safety

Indexed keywords

INFLIXIMAB; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ANALYTIC METHOD; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SURVIVAL RATE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447560051     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0330-9     Document Type: Article

References (26)

1. Gran JT, Husby G (1993) The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 22:319-334
2. Alamanos Y, Papadopoulos NG, Voulgari PV, Karakatsanis A, Siozos C, Drosos AA (2004) Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002. Rheumatology (Oxford) 43:615-618
3. Braun J, Sieper J, Bollow M (2000) Imaging of sacroiliitis. Clin Rheumatol 19:51-57
4. van der Horst-Bruinsma IE, Clegg DO, Dijkmans BA (2002) Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol 20 (6 Suppl 28):S67-S70
5. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346-1352
6. Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielant H, Veys EM (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthopathy. Arthritis Rheum 46:755-765
7. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359(9313):1187-1193
8. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Reddig J, Sieper J (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 48:2224-2233
9. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, Euller-Ziegler L, Sibilia J, Perdriger A, Mezieres M, Alexandre C, Dougados M (2002) Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 41:1280-1285
10. [No authors listed] (2005) TNF antagonists for ankylosing spondylitis. Drug Ther Bull 43:19-22
11. Braun J, Baraliakos X, Brandt J, Sieper J (2005) Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 34:178-190
12. De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Verbruggen G, Mielants H, Veys EM (2004) Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis. Drugs 64:2793-2811
13. Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, Drosos AA (2003) Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 62:1218-1220
14. Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA (2005) Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 64:940-942
15. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Sieper J (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64:229-234
16. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Sieper J (2005) Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44:670-676
17. Gossec L, Le Henanff A, Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, Euller-Ziegler L, Sibilia J, Perdriger A, Alexandre C, Dougados M et al (2006) Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up. Rheumatology (Oxford) 45:859-862
18. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
19. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286-2291
20. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J (2004) Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 63:1438-1444
21. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281-2285
22. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876-1886
23. Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J (2003) Biologic therapies in the spondyloarthritis: new opportunities, new challenges. Curr Opin Rheumatol 15:394-407
24. Robinson DM, Keating GM (2005) Infliximab: in ankylosing spondylitis. Drugs 65:1283-1294
25. Keeling S, Oswald A, Russell AS, Maksymowych WP (2006) Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup. J Rheumatol 33:558-561
26. Maksymowych WP, Inman RD, Gladman D, Thomson G, Stone M, Karsh J, Russell AS; Spondyloarthritis Research Consortium of Canada (SPARCC) (2003) Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 30:1356-1363